Advising travellers beyond infectious diseases: Can we learn from our forebears?

J Travel Med

Department Primary Health Care and General Practice, University of Otago, Wellington 6023, New Zealand.

Published: August 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1093/jtm/taac091DOI Listing

Publication Analysis

Top Keywords

advising travellers
4
travellers infectious
4
infectious diseases
4
diseases learn
4
learn forebears?
4
advising
1
infectious
1
diseases
1
learn
1
forebears?
1

Similar Publications

Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123 monocytes and plasmacytoid dendritic cells (pDCs). pDC bone marrow clusters in CMML have been associated with higher rates of acute myeloid leukemia transformation. We evaluated tagraxofusp, a CD123-targeted therapy, in a phase 1/2 trial for patients with CMML.

View Article and Find Full Text PDF

Background: Although there is a rising trend in both dengue cases and immunocompromised conditions, there is limited research on how common severe dengue is in immunocompromised individuals. This data is key for those advising the ever-increasing numbers of immunocompromised travellers.

Methods: We conducted a systematic review and meta-analysis of studies reporting dengue frequency or outcomes in immunocompromised populations.

View Article and Find Full Text PDF

HPV vaccination in adults provides opportunities for individuals who were previously ineligible, or who missed vaccination as adolescents, thereby reducing HPV-related disease burden. This targeted literature review summarizes the HPV vaccination recommendations and guidelines by National Immunization Technical Advisory Groups and professional societies, and public funded programs for adults. Of the 152 jurisdictions examined, 62 offered HPV vaccination recommendations for general adults.

View Article and Find Full Text PDF

Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.

J Neurol Neurosurg Psychiatry

September 2025

Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuroinflammation, Bron, France.

Unlabelled: BackgroundTarget trial emulation (TTE) offers a formal framework for causal inference using observational data, but its validity must be evaluated in each research domain by replicating randomised clinical trials (RCTs). We aimed to replicate eight RCTs evaluating the efficacy of disease-modifying therapies (DMTs) in multiple sclerosis (MS) using French registry data.

Methods: This multicentre, retrospective, observational study was conducted using data extracted in December 2023 from the (OFSEP) database.

View Article and Find Full Text PDF

Background: No standard treatment exists for patients with platinum-refractory advanced type B3 thymoma and thymic carcinoma. In the PECATI trial, we sought to assess the antitumour activity and safety of lenvatinib plus pembrolizumab in this population.

Methods: In this single-arm phase 2 trial, we recruited participants from 11 hospitals in France, Italy, and Spain.

View Article and Find Full Text PDF